The Dexcom emblem seems on smartphone screens and backgrounds.
Pavlo Gonchar | Sopa Photographs | Gentle Rocket | Getty Photographs
shares Dexcon The diabetes administration firm fell greater than 33% in after-hours buying and selling Thursday after the diabetes administration firm reported disappointing second-quarter income and offered weak steering.
Right here’s what the corporate does:
- Earnings per share: Adjusted to 43 cents, in contrast with LSEG forecast of 39 cents
- revenue: $ 1 billion, and LSEG is predicted to be 1.04 billion US {dollars}
Dexcom’s income elevated 15% from $871.3 million a 12 months earlier, in response to a press launch. The corporate reported internet revenue of $143.5 million, up from $115.9 million in the identical interval final 12 months.
Dexcom mentioned it expects third-quarter income to be within the vary of $975 million to $1 billion, taking into consideration “sure distinctive objects impacting 2024 seasonality.”
“Whereas Dexcom superior a number of key strategic initiatives within the second quarter, our execution didn’t meet our excessive requirements,” Dexcom CEO Kevin Sayer mentioned within the launch. “We now have a singular alternative to leverage our variations to With a complete product portfolio serving tens of millions of consumers all over the world, we’re taking actions to enhance execution and greatest place ourselves for continued long-term progress.”
That is breaking information. Please refresh for updates.
